← Eichor
Study identifier: NCT06280482 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

Condition: Smooth Muscle Dysfunction Syndrome (SMDS)  ·  Sponsor: The University of Texas Health Science Center, Houston

PhasePhase 1
Planned participants15
Who can joinAll sexes, 1 Year to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.

This description comes directly from the study's public registry record.

Talk to the study team

Dianna M Milewicz, MD, PhD  ·  (713) 500-6725  ·  Dianna.M.Milewicz@uth.tmc.edu

David R Murdock, MD  ·  (713) 500-6735  ·  David.R.Murdock@uth.tmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas Health Science Center at HoustonHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06280482